35857 membres inscrits Accès abonné revues  Aide   Newsletter    Me connecter
Les Communiqués
 
 
     Nasdaq OMX
 
Rechercher dans le flux Nasdaq GlobeNewswire
Rechercher
SPINEWAY : 2016 sales revenue, major operational developments and goals for 2018 confirmed
Thu, 19 01 2017 16:45:00
Press release                                                                                                    Ecully, 19 January 2017 2016 sales revenue Major operational developments (...)
SPINEWAY :Chiffre d'affaires 2016, développements opérationnels majeurs et objectifs 2018 confirmés
Thu, 19 01 2017 16:45:00
Communiqué de presse                                                                                               Ecully, le 19 janvier 2017 Chiffre d'affaires 2016 Développements opérationnels majeurs (...)
Agfa-Gevaert: Publication of a transparency notification - Regulated information
Thu, 19 01 2017 16:40:00
(Article 14 of the law of May 2, 2007 on the disclosure of significant shareholdings) Mortsel, Belgium - January 19, 2017 - 5.40 p.m. CET  According to Agfa-Gevaert NV's bylaws, the threshold as from which a shareholding needs to be (...)
Summit Therapeutics plc : Exercise of Options
Thu, 19 01 2017 16:11:06
Summit Therapeutics plc ("Summit", the "Company" or the "Group") EXERCISE OF SHARE OPTIONS Oxford, UK, 19 January 2017 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug (...)
AbCellera Receives Grant to Help Fight Tuberculosis
Thu, 19 01 2017 14:00:00
AbCellera received a grant from the Bill & Melinda Gates Foundation to discover antibodies against  Mycobacterium tuberculosis . VANCOUVER, British Columbia, Jan. 19, 2017 (GLOBE NEWSWIRE) -- AbCellera today announced a grant (...)
MPI's spinout Oncology Venture granted EUROSTARS funding for PoC of LiPlaCis
Thu, 19 01 2017 13:31:03
Hoersholm, Denmark, January 19 th , 2017 - Medical Prognosis Institute A/S (MPI.ST) (Denmark and Phoenix, AZ, USA) today announced that Oncology Venture Sweden AB (OV.ST) a spinout from MPI and OV's (...)
PCI Biotech: Capital increase registered and listing of new shares
Thu, 19 01 2017 12:46:40
Oslo, 19 January 2017, Reference is made to the previous announcements by PCI Biotech Holding ASA ("PCI Biotech" or the "Company") in respect of the fully underwritten rights issue of 10,000,000 new shares in the Company (the (...)
Abeona Therapeutics Receives Orphan Drug Designation in The European Union for ABO-101 Gene Therapy in Sanfilippo Syndrome Type B
Thu, 19 01 2017 12:43:00
NEW YORK and CLEVELAND, Jan. 19, 2017 (GLOBE NEWSWIRE) -- ABO-101, Abeona's third AAV gene therapy program to receive EMA Orphan Designation Clinical trials anticipated to begin enrolling in second quarter 2017 (...)
AroCell: Nomination committee appointed for Annual General Meeting 2017
Thu, 19 01 2017 10:10:00
A decision was taken on May 18, 2016 at the Annual General Meeting for AroCell AB (publ) that a nomination committee should be appointed and should consist of three members, comprised of the three largest shareholders on September 30, 2016, and (...)
UPM BioVerno and GrowDex® chosen among 25 unique example cases of Nordic bioeconomy
Thu, 19 01 2017 09:00:00
(UPM, 19 January 2017 at 11:00 EET) - The Nordic Bioeconomy Panel under The Nordic Council of Ministers has chosen UPM BioVerno and GrowDex® in the Nordic bioeconomy - 25 cases for sustainable change catalogue. UPM BioVerno is a renewable (...)
Summit Appoints Dr David Roblin as Chief Operating Officer and President of Research & Development
Wed, 18 01 2017 12:00:00
Summit Therapeutics plc ('Summit', 'Company' or the 'Group') SUMMIT APPOINTS DR DAVID ROBLIN AS CHIEF OPERATING OFFICER AND PRESIDENT OF RESEARCH & DEVELOPMENT Oxford, UK, 18 January (...)
Apricus Biosciences Announces Approval of Vitaros® for the Treatment of Erectile Dysfunction in Mexico
Wed, 18 01 2017 12:00:00
Ferring Plans to Launch in Mexico and Argentina During the Second Quarter 2017 SAN DIEGO, Jan. 18, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines (...)
DXS International plc : Half-yearly report
Wed, 18 01 2017 10:00:00
XS INTERNATIONAL PLC INTERIM RESULTS for the half year ending 31 st October 2016 The Board of DXS International Plc ("DXS" or the "Company"), the ISDX quoted developer and supplier of (...)
Sanofi : Informations relatives au nombre total de droits de vote et d'actions prévues par l'article L. 233-8 II du Code de commerce et l'article 223-16 du Règlement général de l'Autorité des Marc...
Wed, 18 01 2017 09:49:39
Informations relatives au nombre total de droits de vote et d'actions prévues par l'article L. 233-8 II du Code de commerce et l'article 223-16 du Règlement général de l'Autorité des Marchés Financiers Sanofi (...)
Sanofi: Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the ...
Wed, 18 01 2017 09:49:39
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l'Autorité (...)
Nexstim Plc issues shares in standby equity distribution agreement pursuant to the financing arrangement announced on 21 July 2016
Wed, 18 01 2017 07:00:00
  Nexstim Plc (NXTMH:HEX, NXTMS:STO) (" Nexstim " or the " Company "), a medical technology company with a pioneering navigated non-invasive brain stimulation system, announces that, pursuant to the (...)
MITHRA ANNOUNCES US PATENT ALLOWANCE FOR THE USE OF ESTETROL AS EMERGENCY CONTRACEPTIVE
Wed, 18 01 2017 06:30:00
PRESS RELEASE MITHRA ANNOUNCES US PATENT ALLOWANCE FOR THE USE OF ESTETROL AS EMERGENCY CONTRACEPTIVE Liège, Belgium, 18 January 2017 - Mithra Pharmaceuticals (Euronext Brussels: MITRA), a company focused on women's (...)
MDxHealth Announces Horizon Blue Cross Blue Shield of New Jersey Issues Positive Coverage Policy on ConfirmMDx
Wed, 18 01 2017 06:00:00
NEWS RELEASE                              REGULATED INFORMATION                            INSIDE INFORMATION               Decision provides access to more than 3.8 million members   IRVINE, CA, and HERSTAL, BELGIUM - (...)
ABLYNX ANNOUNCES WARRANT EXERCISE
Wed, 18 01 2017 06:00:00
REGULATED INFORMATION GHENT, Belgium, 18 January 2017 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in conformity with Title II of the Law of 2 May 2007 and the Royal Decree of 14 February (...)
Les données de XBiotech de la phase 3 pour le traitement du cancer colorectal ont été publiées dans The Lancet Oncology
Wed, 18 01 2017 00:14:31
Le rapport souligne l'efficacité du nouveau traitement par anticorps contre le cancer colorectal avancé AUSTIN, Texas, le 18 janvier 2017 (GLOBE NEWSWIRE) - XBiotech Inc. (NASDAQ : XBIT) a annoncé aujourd'hui la publication des (...)
Dr. Walid Abi-Saab joins Galapagos as Chief Medical Officer
Tue, 17 01 2017 21:00:00
   Mechelen, Belgium; 17 January 2017 - Galapagos NV (Euronext & NASDAQ: GLPG) announces the appointment of Dr. Walid Abi-Saab to the role of Chief Medical Officer, beginning on 1 March 2017. The Chief Medical Officer will be a member (...)
EU approval of Suliqua(TM) triggers USD 10 million milestone payment to Zealand
Tue, 17 01 2017 19:09:55
Company announcement - No. 2/2017 EU approval of Suliqua(TM) triggers USD 10 million milestone payment to Zealand          Suliqua(TM) approved in the EU for treatment of adults with type 2 (...)
Sanofi : Approbation de SuliquaTM dans l'Union européenne pour le traitement du diabète de type 2 de l'adulte
Tue, 17 01 2017 18:20:22
Approbation de Suliqua TM dans l'Union européenne pour le traitement du diabète de type 2 de l'adulte Paris, France - Le 18 janvier 2017 - Sanofi annonce aujourd'hui que la Commission européenne (...)
Sanofi: SuliquaTM Approved in the European Union for the Treatment of Adults with Type 2 Diabetes
Tue, 17 01 2017 18:20:22
 Suliqua TM Approved in the European Union for the Treatment of Adults with Type 2 Diabetes Paris, France - January 18th , 2017 - Sanofi announced today that the European Commission has granted (...)
Virbac : annual sales growth of 4.5%, at constant exchange rates
Tue, 17 01 2017 16:45:00
Virbac: annual sales growth of 4.5%, at constant exchange rates Public release - January 17 th , 2017 Virbac consolidated revenue in the fourth quarter reached 225.7 M?, a significant +9.2% growth (...)
publicités
publicité
 
  KauriWeb

Afficher toutes les thématiques